Maxim Pharmaceuticals regulatory update

MMP received U.S. Patent No. 5,834,246 covering recombinant systems for the expression of the Cholera B-Subunit (rCTB). The company's MaxVax mucosal vaccine technology uses rCTB as an adjuvant for imm...